Efficacy of Drug X in Metastatic Lung Cancer: A Phase 3 Study
Phase 3 study demonstrates significant improvement in progression-free survival with Drug X in metastatic NSCLC patients.
American Society of Clinical Oncology Annual Meeting 2024